Feb 27 |
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 24 |
Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week
|
Feb 23 |
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
|
Feb 21 |
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
|
Feb 20 |
Arvinas announces CFO Sean Cassidy's departure
|
Feb 20 |
Arvinas Announces Chief Financial Officer Transition
|
Feb 20 |
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
|
Feb 14 |
Citi downgrades Arvinas to neutral, cites valuation
|
Feb 14 |
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
|
Feb 8 |
Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside
|